iBio, a biologics contract manufacturing organization and biotechnology innovator, has signed two Master Services Agreements (MSAs) and a Memorandum of Understanding (MoU) with the Infectious Disease Research Institute (IDRI) in support of iBio’s SARS-CoV-2 Virus-Like Particle (VLP) vaccine development.   Under the MSAs, IDRI will support pre-clinical development and provide clinical trial oversight, while iBio will provide process development and manufacturing services to IDRI, as needed. Addit...